BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 1742491)

  • 21. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin.
    Finke J; Bertz H; Schmoor C; Veelken H; Behringer D; Wäsch R; Kunzmann R; Heidecker L; Lang H; Meyer-König U; Mertelsmann R
    Br J Haematol; 2000 Oct; 111(1):303-13. PubMed ID: 11091217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
    Zuffa E; Bandini G; Bonini A; Santucci MA; Martinelli G; Rosti G; Testoni N; Zaccaria A; Tura S
    Haematologica; 1998 Mar; 83(3):231-6. PubMed ID: 9573677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.
    Ozer H; George SL; Schiffer CA; Rao K; Rao PN; Wurster-Hill DH; Arthur DD; Powell B; Gottlieb A; Peterson BA; Rai K; Testa JR; LeBeau M; Tantravahi R; Bloomfield CD
    Blood; 1993 Nov; 82(10):2975-84. PubMed ID: 8219189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Colony growth in cultures from bone marrow and peripheral blood after curative treatment for leukemia and severe aplastic anemia.
    Betticher DC; Huxol H; Müller R; Speck B; Nissen C
    Exp Hematol; 1993 Nov; 21(12):1517-21. PubMed ID: 8405233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of outcome of allogeneic bone marrow transplantation with and without granulocyte colony-stimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia.
    Ji SQ; Chen HR; Wang HX; Yan HM; Pan SP; Xun CQ
    Biol Blood Marrow Transplant; 2002; 8(5):261-7. PubMed ID: 12064363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Unrelated donor allogenetic marrow transplantation in treatment of acute and chronic leukemia].
    Huang H; Lin M; Meng H
    Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):263-7. PubMed ID: 11798883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different response to recombinant human granulocyte-macrophage colony-stimulating factor in primary and secondary graft failure after bone marrow transplantation.
    Sierra J; Terol MJ; Urbano-Ispizua A; Rovira M; Marin P; Carreras E; Batlle M; Rozman C
    Exp Hematol; 1994 Jul; 22(7):566-72. PubMed ID: 8013572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Samuel S; Kapelushnik J; Brautbar C; Or R
    Blood; 1996 Mar; 87(6):2195-204. PubMed ID: 8630379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alpha-2b-interferon as single therapy for patients with chronic myeloid leukemia relapsing after T-cell depleted allogeneic bone marrow transplantation.
    Arcese W; Mauro FR; Screnci M; Alimena G; Iori AP; De Cuia MR; Lo Coco F; Montefusco E; Fazi P; Mandelli F
    Eur J Haematol Suppl; 1990; 52():36-9. PubMed ID: 2279545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Engraftment following mitoxantrone (Mito) based conditioning for allogeneic bone marrow transplantation (allo-BMT).
    Nagler A; Soni S; Samuel S; Or R
    Leuk Res; 1998 Mar; 22(3):209-13. PubMed ID: 9619912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute graft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies.
    von Bueltzingsloewen A; Belanger R; Perreault C; Bonny Y; Roy DC; Lalonde Y; Boileau J; Kassis J; Lavallee R; Lacombe M
    Blood; 1993 Feb; 81(3):849-55. PubMed ID: 8427977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hematopoietic and immune recovery after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation in a pediatric population.
    Nagatoshi Y; Kawano Y; Watanabe T; Abe T; Okamoto Y; Kuroda Y; Takaue Y; Okamura J
    Pediatr Transplant; 2002 Aug; 6(4):319-26. PubMed ID: 12234273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Soluble interferon-gamma receptor and interferon-gamma in patients undergoing allogeneic bone marrow transplantation for hematological malignancies.
    Toren A; Barak V; Novick D; Nagler A
    Cytokines Cell Mol Ther; 1997 Sep; 3(3):153-8. PubMed ID: 9426973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation.
    Schriber JR; Chao NJ; Long GD; Negrin RS; Tierney DK; Kusnierz-Glaz C; Lucas KS; Blume KG
    Blood; 1994 Sep; 84(5):1680-4. PubMed ID: 7520782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis.
    Pettengell R; Morgenstern GR; Woll PJ; Chang J; Rowlands M; Young R; Radford JA; Scarffe JH; Testa NG; Crowther D
    Blood; 1993 Dec; 82(12):3770-7. PubMed ID: 7505124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined transplantation of allogeneic bone marrow and CD34+ blood cells.
    Link H; Arseniev L; Bähre O; Berenson RJ; Battmer K; Kadar JG; Jacobs R; Casper J; Kühl J; Schubert J; Diedrich H; Poliwoda H
    Blood; 1995 Oct; 86(7):2500-8. PubMed ID: 7545459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of alpha-interferon augmentation of cyclosporine-induced graft versus host disease in recipients of autologous bone marrow transplantation.
    Ratanatharathorn V; Uberti J; Karanes C; Lum LG; Abella E; Dan ME; Hussein M; Sensenbrenner LL
    Bone Marrow Transplant; 1994 May; 13(5):625-30. PubMed ID: 8054915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose.
    Drobyski WR; Keever CA; Roth MS; Koethe S; Hanson G; McFadden P; Gottschall JL; Ash RC; van Tuinen P; Horowitz MM
    Blood; 1993 Oct; 82(8):2310-8. PubMed ID: 8400284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.